These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15566638)

  • 1. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
    Wang SS; Guan ZZ; Xiang YQ; Jiang WQ; Lin TY; Zhang L
    Ai Zheng; 2004 Nov; 23(11 Suppl):1365-9. PubMed ID: 15566638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor ZD1839 on nasopharyngeal carcinoma cells].
    Wang SS; Guan ZZ; Jiang WQ; Lin TY; Zhang L
    Ai Zheng; 2004 May; 23(5):540-4. PubMed ID: 15142450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.
    Gu WG; Huang Y; Yuan ZY; Peng RJ; Luo HT; He ZR; Wang SS
    Asian Pac J Cancer Prev; 2013; 14(3):1787-90. PubMed ID: 23679274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
    Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
    FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
    Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
    Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preliminary study of 18F-FLT micro-PET/CT in predicting radiosensitivity of human nasopharyngeal carcinoma xenografts.
    Zheng Y; Yang Z; Zhang Y; Shi Q; Bao X; Zhang J; Yuan H; Yao Z; Hu C; Zhang Y
    Ann Nucl Med; 2015 Jan; 29(1):29-36. PubMed ID: 25217247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
    Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
    Zhao XM; Pan SY; Huang QL; Lu YN; Wu XH; Chang JH; Liu ZB; Cai XW; Liu Q; Wang JL; Fu XL
    Oncotarget; 2016 Aug; 7(31):49384-49396. PubMed ID: 27283902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells.
    Liu Z; Liu J; Li L; Nie D; Tao Q; Wu J; Fan J; Lin C; Zhao S; Ju D
    PLoS One; 2015; 10(8):e0135236. PubMed ID: 26288183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.
    Ma BB; Lui VW; Poon FF; Wong SC; To KF; Wong E; Chen H; Lo KW; Tao Q; Chan AT; Ng MH; Cheng SH
    Invest New Drugs; 2010 Jun; 28(3):326-33. PubMed ID: 19756373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.